|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Amortization of acquisition related intangibles | |||||
| Change in fair value of contingent consideration | |||||
| Change in fair value | |||||
| Restructuring | |||||
| Total operating expenses | |||||
| Operating income (loss) | |||||
| Interest income, net | |||||
| China dissolution | |||||
| Other expense, net | |||||
| Income (loss) before income tax (benefit) expense | |||||
| Income tax (benefit) expense | |||||
| Net income (loss) | |||||
| Net income (loss) per common share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average number of common shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
